BridgeBio Pharma, Inc. (BBIO)
67.25
+0.34
(+0.51%)
USD |
NASDAQ |
Oct 02, 16:00
67.23
-0.02
(-0.03%)
After-Hours: 20:00
BridgeBio Pharma Net Income (Quarterly) : -155.89M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -155.89M |
| March 31, 2026 | -166.56M |
| December 31, 2025 | -194.64M |
| September 30, 2025 | -184.94M |
| June 30, 2025 | -183.76M |
| March 31, 2025 | -169.61M |
| December 31, 2024 | -267.39M |
| September 30, 2024 | -164.25M |
| June 30, 2024 | -75.54M |
| March 31, 2024 | -36.16M |
| December 31, 2023 | -170.33M |
| September 30, 2023 | -179.49M |
| June 30, 2023 | -160.70M |
| March 31, 2023 | -142.73M |
| December 31, 2022 | -140.57M |
| September 30, 2022 | -140.19M |
| June 30, 2022 | -2.559M |
| Date | Value |
|---|---|
| March 31, 2022 | -201.33M |
| December 31, 2021 | -152.28M |
| September 30, 2021 | -161.02M |
| June 30, 2021 | -102.07M |
| March 31, 2021 | -171.08M |
| December 31, 2020 | -135.02M |
| September 30, 2020 | -130.17M |
| June 30, 2020 | -136.21M |
| March 31, 2020 | -104.08M |
| December 31, 2019 | -84.15M |
| September 30, 2019 | -60.66M |
| June 30, 2019 | -74.33M |
| March 31, 2019 | -69.44M |
| December 31, 2018 | -49.24M |
| September 30, 2018 | -42.08M |
| June 30, 2018 | -35.70M |
| March 31, 2018 | -42.43M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Ionis Pharmaceuticals, Inc. | -114.65M |
| Pfizer Inc. | -246.00M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
| Vertex Pharmaceuticals, Inc. | 1.100B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 243.68M |
| Total Expenses (Quarterly) | 395.89M |
| EPS Diluted (Quarterly) | -0.7775 |
| Enterprise Value | 15.82B |
| Gross Profit Margin (Quarterly) | 93.68% |
| Profit Margin (Quarterly) | -63.97% |
| Earnings Yield | -5.31% |
| Normalized Earnings Yield | -5.306 |